Autors: Ilie O.D., Văcărean-Trandafir I.C., Amărandi R.M., Nita I.B., Dobrin P.R., Doroftei M., Ivanov I.C., Savuta G., Kirov, B. B., Doroftei B.
Title: Exploring gut microbiota alterations in Parkinson’s disease: insights from a 16S amplicon sequencing Eastern European pilot study
Keywords: 16S rRNA, amplicon sequencing, dopaminergic agonists, gut microbiome, MiSeq, Parkinson’s disease

Abstract: Copyright Introduction: Parkinson’s disease (PD) is a neurodegenerative disorder increasingly associated with alterations in gut microbiota through the gut–brain axis (GBA). Despite growing global interest, studies examining microbiota composition in Eastern European populations remain limited. Methods: We profiled the gut microbiota of 59 Romanian individuals using 16S rRNA gene sequencing targeting the V3–V4 region. After quality filtering, 39 subjects (19 PD patients and 20 healthy controls [HC]) were retained for downstream analysis. Clinical metadata were collected to assess potential confounders, including age, sex, metabolic parameters, lifestyle, and comorbidities. Results: PD patients differed significantly from HCs in glycemia (p = 0.02), cholesterol (p = 0.027), and LDL levels (p = 0.047), and more frequently presented with restrictive diets and comorbidities such as cardiovascular disease and diabetes. While α-diversity metrics did not differ significantly between groups, principal coordinate analysis (PCoA) based on Aitchison distance showed moderate compositional separation. Permutational multivariate analysis of variance (PERMANOVA) confirmed that disease status was a significant driver of gut microbiota composition (R2 = 5.3%, p = 0.002), independent of clinical and lifestyle covariates. Sparse partial least square linear discriminant (sPLS-DA) identified several genera distinguishing PD from HC, with Mogibacterium and RikenellaceaeRC9 gut group enriched in PD, and several known short-chain fatty acid (SCFA)-producing genera (Fusicatenibacter, Lachnospiraceae UCG-001, Butyricicoccus, Anaerostipes) enriched in HCs. Linear discriminant analysis (LDA) Effect Size (LEfSe) corroborated these findings, confirming the differential abundance of several SCFA-producing genera in the HC group. Discussion: Our results reveal distinct microbial signatures associated with PD in this Romanian cohort, marked by a consistent depletion of SCFA-producing bacteria in patients. These findings support the role of gut microbiota in PD pathophysiology and underscore the need for further studies in Eastern European populations.

References

  1. Aho V. T. E. Houser M. C. Pereira P. A. B. Chang J. Rudi K. Paulin L. et al. (2021). Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease. Mol. Neurodegener. 16:6. doi: 10.1186/s13024-021-00427-6, PMID: 33557896
  2. Aho V. T. E. Pereira P. A. B. Voutilainen S. Paulin L. Pekkonen E. Auvinen P. et al. (2019). Gut microbiota in Parkinson’s disease: temporal stability and relations to disease progression. EBioMedicine 44, 691–707. doi: 10.1016/j.ebiom.2019.05.064, PMID: 31221587
  3. Almamoun R. Pierozan P. Manoharan L. Karlsson O. (2023). Altered gut microbiota community structure and correlated immune system changes in dibutyl phthalate exposed mice. Ecotoxicol. Environ. Saf. 262:115321. doi: 10.1016/j.ecoenv.2023.115321, PMID: 37549549
  4. Babacan Yildiz G. Kayacan Z. C. Karacan I. Sumbul B. Elibol B. Gelisin O. et al. (2023). Altered gut microbiota in patients with idiopathic Parkinson’s disease: an age-sex matched case-control study. Acta Neurol. Belg. 123, 999–1009. doi: 10.1007/s13760-023-02195-0, PMID: 36719617
  5. Bai F. You L. Lei H. Li X. (2024). Association between increased and decreased gut microbiota abundance and Parkinson’s disease: a systematic review and subgroup meta-analysis. Exp. Gerontol. 191:112444. doi: 10.1016/j.exger.2024.112444, PMID: 38679353
  6. Baldini F. Hertel J. Sandt E. Thinnes C. C. Neuberger-Castillo L. Pavelka L. et al. (2020). Parkinson’s disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions. BMC Biol. 18:62. doi: 10.1186/s12915-020-00775-7, PMID: 32517799
  7. Barichella M. Pacchetti C. Bolliri C. Cassani E. Iorio L. Pusani C. et al. (2016). Probiotics and prebiotic fiber for constipation associated with Parkinson disease. Neurology 87, 1274–1280. doi: 10.1212/WNL.0000000000003127, PMID: 27543643
  8. Barichella M. Severgnini M. Cilia R. Cassani E. Bolliri C. Caronni S. et al. (2019). Unraveling gut microbiota in Parkinson’s disease and atypical parkinsonism. Mov. Disord. 34, 396–405. doi: 10.1002/mds.27581, PMID: 30576008
  9. Bedarf J. R. Hildebrand F. Coelho L. P. Sunagawa S. Bahram M. Goeser F. et al. (2017). Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients. Genome Med. 9:39. doi: 10.1186/s13073-017-0428-y, PMID: 28449715
  10. Ben-Shlomo Y. Darweesh S. Llibre-Guerra J. Marras C. San Luciano M. Tanner C. (2024). The epidemiology of Parkinson’s disease. Lancet 403, 283–292. doi: 10.1016/S0140-6736(23)01419-8, PMID: 38245248
  11. Boertien J. M. Murtomäki K. Pereira P. A. B. van der Zee S. Mertsalmi T. H. Levo R. et al. (2022). Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease. NPJ Parkinsons Dis. 8:129. doi: 10.1038/s41531-022-00395-8, PMID: 36216843
  12. Braak H. Del Tredici K. Bratzke H. Hamm-Clement J. Sandmann-Keil D. Rüb U. (2002). Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). J. Neurol. 249 Suppl 3, III/1–III/5. doi: 10.1007/s00415-002-1301-4, PMID: 12528692
  13. Braak H. Del Tredici K. Rüb U. de Vos R. A. I. Jansen Steur E. N. H. Braak E. (2003b). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 24, 197–211. doi: 10.1016/S0197-4580(02)00065-9, PMID: 12498954
  14. Braak H. Rüb U. Gai W. P. Del Tredici K. (2003a). Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 110, 517–536. doi: 10.1007/s00702-002-0808-2, PMID: 12721813
  15. Callahan B. J. Sankaran K. Fukuyama J. A. McMurdie P. J. Holmes S. P. (2016). Bioconductor workflow for microbiome data analysis: from raw reads to community analyses. F1000Res 5:1492. doi: 10.12688/f1000research.8986.2, PMID: 27508062
  16. Cao Y. Dong Q. Wang D. Zhang P. Liu Y. Niu C. (2022). microbiomeMarker: an R/Bioconductor package for microbiome marker identification and visualization. Bioinformatics 38, 4027–4029. doi: 10.1093/bioinformatics/btac438, PMID: 35771644
  17. Cardona S. Eck A. Cassellas M. Gallart M. Alastrue C. Dore J. et al. (2012). Storage conditions of intestinal microbiota matter in metagenomic analysis. BMC Microbiol. 12:158. doi: 10.1186/1471-2180-12-158, PMID: 22846661
  18. Cersosimo M. G. (2015). Gastrointestinal biopsies for the diagnosis of alpha-Synuclein pathology in Parkinson’s disease. Gastroenterol. Res. Pract. 2015:476041. doi: 10.1155/2015/476041, PMID: 26078752
  19. Chassard C. Dapoigny M. Scott K. P. Crouzet L. Del’homme C. Marquet P. et al. (2012). Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment. Pharmacol. Ther. 35, 828–838. doi: 10.1111/j.1365-2036.2012.05007.x
  20. Chaudhuri K. R. Healy D. G. Schapira A. H. V. (2006). Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 5, 235–245. doi: 10.1016/S1474-4422(06)70373-8, PMID: 16488379
  21. Chen W. Bi Z. Zhu Q. Gao H. Fan Y. Zhang C. et al. (2021). An analysis of the characteristics of the intestinal flora in patients with Parkinson’s disease complicated with constipation. Am. J. Transl. Res. 13, 13710–13722. Available online at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8748098/
  22. Chen J. Bittinger K. Charlson E. S. Hoffmann C. Lewis J. Wu G. D. et al. (2012). Associating microbiome composition with environmental covariates using generalized UniFrac distances. Bioinformatics 28, 2106–2113. doi: 10.1093/bioinformatics/bts342, PMID: 22711789
  23. Chen S.-J. Chen C.-C. Liao H.-Y. Lin Y.-T. Wu Y.-W. Liou J.-M. et al. (2022). Association of Fecal and Plasma Levels of short-chain fatty acids with gut microbiota and clinical severity in patients with Parkinson disease. Neurology 98, e848–e858. doi: 10.1212/WNL.0000000000013225, PMID: 34996879
  24. Choo J. M. Leong L. E. X. Rogers G. B. (2015). Sample storage conditions significantly influence faecal microbiome profiles. Sci. Rep. 5:16350. doi: 10.1038/srep16350, PMID: 26572876
  25. Cilia R. Piatti M. Cereda E. Bolliri C. Caronni S. Ferri V. et al. (2021). Does gut microbiota influence the course of Parkinson’s disease? A 3-year prospective exploratory study in de novo patients. J. Parkinsons Dis. 11, 159–170. doi: 10.3233/JPD-202297, PMID: 33337387
  26. Cirstea M. S. Yu A. C. Golz E. Sundvick K. Kliger D. Radisavljevic N. et al. (2020). Microbiota composition and metabolism are associated with gut function in Parkinson’s disease. Mov. Disord. 35, 1208–1217. doi: 10.1002/mds.28052, PMID: 32357258
  27. Clavel T. Lepage P. Charrier C. (2014) in The family coriobacteriaceae BT - the prokaryotes: Actinobacteria. eds. Rosenberg E. DeLong E. F. Lory S. Stackebrandt E. Thompson F. (Berlin, Heidelberg: Springer Berlin Heidelberg), 201–238.
  28. Cryan J. F. Dinan T. G. (2012). Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat. Rev. Neurosci. 13, 701–712. doi: 10.1038/nrn3346, PMID: 22968153
  29. Dalile B. Van Oudenhove L. Vervliet B. Verbeke K. (2019). The role of short-chain fatty acids in microbiota–gut–brain communication. Nat. Rev. Gastroenterol. Hepatol. 16, 461–478. doi: 10.1038/s41575-019-0157-3, PMID: 31123355
  30. Dauer W. Przedborski S. (2003). Parkinson’s disease: mechanisms and models. Neuron 39, 889–909. doi: 10.1016/S0896-6273(03)00568-3, PMID: 12971891
  31. Del Chierico F. Grassini P. Quagliariello A. Torti M. Russo A. Reddel S. et al. (2020). The impact of intestinal microbiota on weight loss in Parkinson’s disease patients: a pilot study. Future Microbiol. 15, 1393–1404. doi: 10.2217/fmb-2019-0336, PMID: 33085540
  32. Deng Y. Umbach A. K. Neufeld J. D. (2024). Nonparametric richness estimators Chao1 and ACE must not be used with amplicon sequence variant data. ISME J. 18:wrae106. doi: 10.1093/ismejo/wrae106, PMID: 38869966
  33. Dickson D. W. Braak H. Duda J. E. Duyckaerts C. Gasser T. Halliday G. M. et al. (2009). Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol. 8, 1150–1157. doi: 10.1016/S1474-4422(09)70238-8, PMID: 19909913
  34. Dorsey E. R. Elbaz A. Nichols E. Abd-Allah F. Abdelalim A. Adsuar J. C. et al. (2018). Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 17, 939–953. doi: 10.1016/S1474-4422(18)30295-3, PMID: 30287051
  35. Dorszewska J. Kowalska M. Prendecki M. Piekut T. Kozłowska J. Kozubski W. (2021). Oxidative stress factors in Parkinson’s disease. Neural Regen. Res. 16, 1383–1391. doi: 10.4103/1673-5374.300980, PMID: 33318422
  36. Dumitrescu L. Marta D. Dănău A. Lefter A. Tulbă D. Cozma L. et al. (2021). Serum and fecal markers of intestinal inflammation and intestinal barrier permeability are elevated in Parkinson’s disease. Front. Neurosci. 15:689723. doi: 10.3389/fnins.2021.689723, PMID: 34220443
  37. DuPont H. L. Suescun J. Jiang Z.-D. Brown E. L. Essigmann H. T. Alexander A. S. et al. (2023). Fecal microbiota transplantation in Parkinson’s disease-a randomized repeat-dose, placebo-controlled clinical pilot study. Front. Neurol. 14:1104759. doi: 10.3389/fneur.2023.1104759, PMID: 36937520
  38. Elbaz A. Carcaillon L. Kab S. Moisan F. (2016). Epidemiology of Parkinson’s disease. Rev. Neurol. 172, 14–26. doi: 10.1016/j.neurol.2015.09.012, PMID: 26718594
  39. Fabbri M. Barbosa R. Rascol O. (2023). Off-time treatment options for Parkinson’s disease. Neurol. Ther. 12, 391–424. doi: 10.1007/s40120-022-00435-8, PMID: 36633762
  40. Forsyth C. B. Shannon K. M. Kordower J. H. Voigt R. M. Shaikh M. Jaglin J. A. et al. (2011). Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease. PLoS One 6:e28032. doi: 10.1371/journal.pone.0028032, PMID: 22145021
  41. Fu S.-C. Lee C.-H. Hsieh Y.-C. Wu P.-H. Lin S.-H. Wang H. (2022a). A pilot study exploring the Association of Entacapone, gut microbiota, and the subsequent side effects in patients with Parkinson’s disease. Front. Cell. Infect. Microbiol. 12:837019. doi: 10.3389/fcimb.2022.837019, PMID: 35463646
  42. Fu S.-C. Shih L.-C. Wu P.-H. Hsieh Y.-C. Lee C.-H. Lin S.-H. et al. (2022b). Exploring the causal effect of constipation on Parkinson’s disease through mediation analysis of microbial data. Front. Cell. Infect. Microbiol. 12:871710. doi: 10.3389/fcimb.2022.871710, PMID: 35646722
  43. Fujio-Vejar S. Vasquez Y. Morales P. Magne F. Vera-Wolf P. Ugalde J. A. et al. (2017). The gut microbiota of healthy Chilean subjects reveals a high abundance of the phylum Verrucomicrobia. Front. Microbiol. 8:1221. doi: 10.3389/fmicb.2017.01221, PMID: 28713349
  44. Gao X. Zhang M. Xue J. Huang J. Zhuang R. Zhou X. et al. (2018). Body mass index differences in the gut microbiota are gender specific. Front. Microbiol. 9:1250. doi: 10.3389/fmicb.2018.01250, PMID: 29988340
  45. Geerlings S. Y. Kostopoulos I. de Vos W. M. Belzer C. (2018). Akkermansia muciniphila in the human gastrointestinal tract: when, where, and how? Microorganisms 6:75. doi: 10.3390/microorganisms6030075, PMID: 30041463
  46. Ghyselinck J. Verstrepen L. Moens F. Van Den Abbeele P. Bruggeman A. Said J. et al. (2021). Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson’s disease. Int. J. Pharm. X 3:100087. doi: 10.1016/j.ijpx.2021.100087
  47. Gobert A. P. Sagrestani G. Delmas E. Wilson K. T. Verriere T. G. Dapoigny M. et al. (2016). The human intestinal microbiota of constipated-predominant irritable bowel syndrome patients exhibits anti-inflammatory properties. Sci. Rep. 6:39399. doi: 10.1038/srep39399, PMID: 27982124
  48. Gomez-Arango L. F. Barrett H. L. Wilkinson S. A. Callaway L. K. McIntyre H. D. Morrison M. et al. (2018). Low dietary fiber intake increases Collinsella abundance in the gut microbiota of overweight and obese pregnant women. Gut Microbes 9, 189–201. doi: 10.1080/19490976.2017.1406584, PMID: 29144833
  49. Gorecka-Mazur A. Krygowska-Wajs A. Furgala A. Li J. Misselwitz B. Pietraszko W. et al. (2024). Associations between gut microbiota characteristics and non-motor symptoms following pharmacological and surgical treatments in Parkinson’s disease patients. Neurogastroenterol. Motil. 36:e14846. doi: 10.1111/nmo.14846, PMID: 38873926
  50. Gryaznova M. Dvoretskaya Y. Burakova I. Syromyatnikov M. Popov E. Kokina A. et al. (2022). Dynamics of changes in the gut microbiota of healthy mice fed with lactic acid Bacteria and Bifidobacteria. Microorganisms 10:1020. doi: 10.3390/microorganisms10051020, PMID: 35630460
  51. Guo X. Tang P. Hou C. Chong L. Zhang X. Liu P. et al. (2022). Integrated microbiome and host transcriptome profiles link Parkinson’s disease to Blautia genus: evidence from feces, blood, and brain. Front. Microbiol. 13:875101. doi: 10.3389/fmicb.2022.875101, PMID: 35722294
  52. Hasegawa S. Goto S. Tsuji H. Okuno T. Asahara T. Nomoto K. et al. (2015). Intestinal Dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson’s disease. PLoS One 10, –e0142164. doi: 10.1371/journal.pone.0142164, PMID: 26539989
  53. Hawkes C. H. Del Tredici K. Braak H. (2007). Parkinson’s disease: a dual-hit hypothesis. Neuropathol. Appl. Neurobiol. 33, 599–614. doi: 10.1111/j.1365-2990.2007.00874.x, PMID: 17961138
  54. Hawkes C. H. Del Tredici K. Braak H. (2009). Parkinson’s disease. Ann. N. Y. Acad. Sci. 1170, 615–622. doi: 10.1111/j.1749-6632.2009.04365.x, PMID: 19686202
  55. Hawkes C. H. Del Tredici K. Braak H. (2010). A timeline for Parkinson’s disease. Parkinsonism Relat. Disord. 16, 79–84. doi: 10.1016/j.parkreldis.2009.08.007, PMID: 19846332
  56. Heintz-Buschart A. Pandey U. Wicke T. Sixel-Döring F. Janzen A. Sittig-Wiegand E. et al. (2018). The nasal and gut microbiome in Parkinson’s disease and idiopathic rapid eye movement sleep behavior disorder. Mov. Disord. 33, 88–98. doi: 10.1002/mds.27105, PMID: 28843021
  57. Henrich M. T. Oertel W. H. Surmeier D. J. Geibl F. F. (2023). Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential. Mol. Neurodegener. 18:83. doi: 10.1186/s13024-023-00676-7, PMID: 37951933
  58. Hertel J. Harms A. C. Heinken A. Baldini F. Thinnes C. C. Glaab E. et al. (2019). Integrated analyses of microbiome and longitudinal metabolome data reveal microbial-host interactions on sulfur metabolism in Parkinson’s disease. Cell Rep. 29, 1767–1777.e8. doi: 10.1016/j.celrep.2019.10.035, PMID: 31722195
  59. Hill-Burns E. M. Debelius J. W. Morton J. T. Wissemann W. T. Lewis M. R. Wallen Z. D. et al. (2017). Parkinson’s disease and Parkinson’s disease medications have distinct signatures of the gut microbiome. Mov. Disord. 32, 739–749. doi: 10.1002/mds.26942, PMID: 28195358
  60. Hughes D. A. Bacigalupe R. Wang J. Rühlemann M. C. Tito R. Y. Falony G. et al. (2020). Genome-wide associations of human gut microbiome variation and implications for causal inference analyses. Nat. Microbiol. 5, 1079–1087. doi: 10.1038/s41564-020-0743-8, PMID: 32572223
  61. Illumina (2013). 16S metagenomic sequencing library preparation. Available online at: https://support.illumina.com/documents/documentation/chemistry_documentation/16s/16s-metagenomic-library-prep-guide-15044223-b.pdf (Accessed June 28, 2024).
  62. Ji T. Huang H. Liu J. Peng T. Zhou X. Tan Q. et al. (2021). Leveraging sequence-based faecal microbial community survey data to identify alterations in gut microbiota among patients with Parkinson’s disease. Eur. J. Neurosci. 53, 687–696. doi: 10.1111/ejn.14952, PMID: 32865266
  63. Jo S. Kang W. Hwang Y. S. Lee S. H. Park K. W. Kim M. S. et al. (2022). Oral and gut dysbiosis leads to functional alterations in Parkinson’s disease. NPJ Parkinsons Dis. 8:87. doi: 10.1038/s41531-022-00351-6, PMID: 35798742
  64. Kembel S. W. Cowan P. D. Helmus M. R. Cornwell W. K. Morlon H. Ackerly D. D. et al. (2010). Picante: R tools for integrating phylogenies and ecology. Bioinformatics 26, 1463–1464. doi: 10.1093/bioinformatics/btq166, PMID: 20395285
  65. Kenna J. E. Chua E. G. Bakeberg M. Tay A. McGregor S. Gorecki A. et al. (2021). Changes in the gut microbiome and predicted functional metabolic effects in an Australian Parkinson’s disease cohort. Front. Neurosci. 15:756951. doi: 10.3389/fnins.2021.756951, PMID: 34776854
  66. Keshavarzian A. Green S. J. Engen P. A. Voigt R. M. Naqib A. Forsyth C. B. et al. (2015). Colonic bacterial composition in Parkinson’s disease. Mov. Disord. 30, 1351–1360. doi: 10.1002/mds.26307, PMID: 26179554
  67. Kim H.-J. Moon C. M. Kang J. L. Park E.-M. (2021). Aging effects on the diurnal patterns of gut microbial composition in male and female mice. Korean J. Physiol. Pharmacol. 25, 575–583. doi: 10.4196/kjpp.2021.25.6.575, PMID: 34697268
  68. Kong F. Hua Y. Zeng B. Ning R. Li Y. Zhao J. (2016). Gut microbiota signatures of longevity. Curr. Biol. 26, R832–R833. doi: 10.1016/j.cub.2016.08.015, PMID: 27676296
  69. Kuai X.-Y. Yao X.-H. Xu L.-J. Zhou Y.-Q. Zhang L.-P. Liu Y. et al. (2021). Evaluation of fecal microbiota transplantation in Parkinson’s disease patients with constipation. Microb. Cell Factories 20:98. doi: 10.1186/s12934-021-01589-0, PMID: 33985520
  70. Lampropoulos I. C. Malli F. Sinani O. Gourgoulianis K. I. Xiromerisiou G. (2022). Worldwide trends in mortality related to Parkinson’s disease in the period of 1994-2019: analysis of vital registration data from the WHO mortality database. Front. Neurol. 13:956440. doi: 10.3389/fneur.2022.956440, PMID: 36267881
  71. Lee H.-S. Lobbestael E. Vermeire S. Sabino J. Cleynen I. (2021). Inflammatory bowel disease and Parkinson’s disease: common pathophysiological links. Gut 70:408. doi: 10.1136/gutjnl-2020-322429, PMID: 33067333
  72. Leite Silva A. B. R. Gonçalves de Oliveira R. W. Diógenes G. P. de Castro Aguiar M. F. Sallem C. C. Lima M. P. P. et al. (2023). Premotor, nonmotor and motor symptoms of Parkinson’s disease: a new clinical state of the art. Ageing Res. Rev. 84:101834. doi: 10.1016/j.arr.2022.101834, PMID: 36581178
  73. Li C. Cui L. Yang Y. Miao J. Zhao X. Zhang J. et al. (2019). Gut microbiota differs between Parkinson’s disease patients and healthy controls in Northeast China. Front. Mol. Neurosci. 12:171. doi: 10.3389/fnmol.2019.00171, PMID: 31354427
  74. Li Z. Liang H. Hu Y. Lu L. Zheng C. Fan Y. et al. (2023). Gut bacterial profiles in Parkinson’s disease: a systematic review. CNS Neurosci. Ther. 29, 140–157. doi: 10.1111/cns.13990, PMID: 36284437
  75. Li Z. Lu G. Li Z. Wu B. Luo E. Qiu X. et al. (2021). Altered Actinobacteria and Firmicutes phylum associated epitopes in patients with Parkinson’s disease. Front. Immunol. 12:632482. doi: 10.3389/fimmu.2021.632482, PMID: 34276644
  76. Li X.-M. Shi X. Yao Y. Shen Y.-C. Wu X.-L. Cai T. et al. (2023). Effects of stool sample preservation methods on gut microbiota biodiversity: new original data and systematic review with Meta-analysis. Microbiol. Spectr. 11:e0429722. doi: 10.1128/spectrum.04297-22, PMID: 37093040
  77. Li F. Wang P. Chen Z. Sui X. Xie X. Zhang J. (2019). Alteration of the fecal microbiota in north-eastern Han Chinese population with sporadic Parkinson’s disease. Neurosci. Lett. 707:134297. doi: 10.1016/j.neulet.2019.134297, PMID: 31200089
  78. Li W. Wu X. Hu X. Wang T. Liang S. Duan Y. et al. (2017). Structural changes of gut microbiota in Parkinson’s disease and its correlation with clinical features. Sci. China Life Sci. 60, 1223–1233. doi: 10.1007/s11427-016-9001-4, PMID: 28536926
  79. Lin C.-H. Chen C.-C. Chiang H.-L. Liou J.-M. Chang C.-M. Lu T.-P. et al. (2019). Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson’s disease. J. Neuroinflammation 16:129. doi: 10.1186/s12974-019-1528-y, PMID: 31248424
  80. Lin A. Zheng W. He Y. Tang W. Wei X. He R. et al. (2018). Gut microbiota in patients with Parkinson’s disease in southern China. Parkinsonism Relat. Disord. 53, 82–88. doi: 10.1016/j.parkreldis.2018.05.007, PMID: 29776865
  81. Lubomski M. Xu X. Holmes A. J. Muller S. Yang J. Y. H. Davis R. L. et al. (2022a). Nutritional intake and gut microbiome composition predict Parkinson’s disease. Front. Aging Neurosci. 14:881872. doi: 10.3389/fnagi.2022.881872, PMID: 35645785
  82. Lubomski M. Xu X. Holmes A. J. Muller S. Yang J. Y. H. Davis R. L. et al. (2022b). The gut microbiome in Parkinson’s disease: a longitudinal study of the impacts on disease progression and the use of device-assisted therapies. Front. Aging Neurosci. 14:875261. doi: 10.3389/fnagi.2022.875261, PMID: 35656540
  83. Luo Y. Qiao L. Li M. Wen X. Zhang W. Li X. (2025). Global, regional, national epidemiology and trends of Parkinson’s disease from 1990 to 2021: findings from the global burden of disease study 2021. Front. Aging Neurosci. 16:1498756. doi: 10.3389/fnagi.2024.1498756, PMID: 39868382
  84. McLaren M. R. Callahan B. J. (2021). Silva 138.1 prokaryotic SSU taxonomic training data formatted for DADA2: Zenodo. Available online at: https://zenodo.org/records/4587955
  85. McMurdie P. J. Holmes S. (2013). Phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One 8:e61217. doi: 10.1371/journal.pone.0061217, PMID: 23630581
  86. Mehanna M. AbuRaya S. Ahmed S. M. Ashmawy G. Ibrahim A. AbdelKhaliq E. (2023). Study of the gut microbiome in Egyptian patients with Parkinson’s disease. BMC Microbiol. 23:196. doi: 10.1186/s12866-023-02933-7, PMID: 37481569
  87. Melis M. Vascellari S. Santoru M. L. Oppo V. Fabbri M. Sarchioto M. et al. (2021). Gut microbiota and metabolome distinctive features in Parkinson disease: focus on levodopa and levodopa-carbidopa intrajejunal gel. Eur. J. Neurol. 28, 1198–1209. doi: 10.1111/ene.14644, PMID: 33185912
  88. Minato T. Maeda T. Fujisawa Y. Tsuji H. Nomoto K. Ohno K. et al. (2017). Progression of Parkinson’s disease is associated with gut dysbiosis: two-year follow-up study. PLoS One 12:e0187307. doi: 10.1371/journal.pone.0187307, PMID: 29091972
  89. Moossavi S. Engen P. A. Ghanbari R. Green S. J. Naqib A. Bishehsari F. et al. (2019). Assessment of the impact of different fecal storage protocols on the microbiota diversity and composition: a pilot study. BMC Microbiol. 19:145. doi: 10.1186/s12866-019-1519-2, PMID: 31253096
  90. Moustafa A. A. Chakravarthy S. Phillips J. R. Gupta A. Keri S. Polner B. et al. (2016). Motor symptoms in Parkinson’s disease: a unified framework. Neurosci. Biobehav. Rev. 68, 727–740. doi: 10.1016/j.neubiorev.2016.07.010, PMID: 27422450
  91. Ngo S. T. Restuadi R. McCrae A. F. Van Eijk R. P. Garton F. Henderson R. D. et al. (2020). Progression and survival of patients with motor neuron disease relative to their fecal microbiota. Amyotroph. Lateral Scler. Frontotemporal Degener. 21, 549–562. doi: 10.1080/21678421.2020.1772825, PMID: 32643435
  92. Nichols E. Steinmetz J. D. Vollset S. E. Fukutaki K. Chalek J. Abd-Allah F. et al. (2022). Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health 7:e105–e125. doi: 10.1016/S2468-2667(21)00249-8, PMID: 34998485
  93. Nishiwaki H. Hamaguchi T. Ito M. Ishida T. Maeda T. Kashihara K. et al. (2020a). Short-chain fatty acid-producing gut microbiota is decreased in Parkinson’s disease but not in rapid-eye-movement sleep behavior disorder. mSystems 5:e00797-20. doi: 10.1128/mSystems.00797-20, PMID: 33293403
  94. Nishiwaki H. Ito M. Hamaguchi T. Maeda T. Kashihara K. Tsuboi Y. et al. (2022). Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease. NPJ Parkinsons Dis. 8:65. doi: 10.1038/s41531-022-00328-5, PMID: 35650236
  95. Nishiwaki H. Ito M. Ishida T. Hamaguchi T. Maeda T. Kashihara K. et al. (2020b). Meta-analysis of gut dysbiosis in Parkinson’s disease. Mov. Disord. 35, 1626–1635. doi: 10.1002/mds.28119, PMID: 32557853
  96. Nuzum N. D. Szymlek-Gay E. A. Loke S. Dawson S. L. Teo W.-P. Hendy A. M. et al. (2023). Differences in the gut microbiome across typical ageing and in Parkinson’s disease. Neuropharmacology 235:109566. doi: 10.1016/j.neuropharm.2023.109566, PMID: 37150399
  97. Oksanen J. Simpson G. Blanchet F. G. Kindt R. Legendre P. Minchin P. et al. (2022). Vegan community ecology package version 2.6-2. Available online at: https://CRAN.R-project.org/package=vegan (Accessed November 20, 2022).
  98. Ottman N. Reunanen J. Meijerink M. Pietilä T. E. Kainulainen V. Klievink J. et al. (2017). Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function. PLoS One 12:e0173004. doi: 10.1371/journal.pone.0173004, PMID: 28249045
  99. Pajares M. Rojo A. I. Manda G. Boscá L. Cuadrado A. (2020). Inflammation in Parkinson’s disease: mechanisms and therapeutic implications. Cells 9:1687. doi: 10.3390/cells9071687, PMID: 32674367
  100. Patel K. Pyrsopoulos N. (2019). “The microbiome and metabolome in alcoholic liver disease” in Microbiome and metabolome in diagnosis, therapy, and other strategic applications (Elsevier), 271–277. doi: 10.1016/B978-0-12-815249-2.00028-2
  101. Pavan S. Gorthi S. P. Prabhu A. N. Das B. Mutreja A. Vasudevan K. et al. (2023). Dysbiosis of the beneficial gut Bacteria in patients with Parkinson’s disease from India. Ann. Indian Acad. Neurol. 26, 908–916. doi: 10.4103/aian.aian_460_23, PMID: 38229613
  102. Pavan S. Prabhu A. N. Prasad Gorthi S. Das B. Mutreja A. Shetty V. et al. (2022). Exploring the multifactorial aspects of gut microbiome in Parkinson’s disease. Folia Microbiol. (Praha) 67, 693–706. doi: 10.1007/s12223-022-00977-2, PMID: 35583791
  103. Peng S. Liu P. Wang X. Li K. (2025). Global, regional and national burden of Parkinson’s disease in people over 55 years of age: a systematic analysis of the global burden of disease study, 1991–2021. BMC Neurol. 25:178. doi: 10.1186/s12883-025-04191-8, PMID: 40269818
  104. Pereira P. A. B. Trivedi D. K. Silverman J. Duru I. C. Paulin L. Auvinen P. et al. (2022). Multiomics implicate gut microbiota in altered lipid and energy metabolism in Parkinson’s disease. NPJ Parkinsons Dis. 8:39. doi: 10.1038/s41531-022-00300-3, PMID: 35411052
  105. Petrov V. A. Saltykova I. V. Zhukova I. A. Alifirova V. M. Zhukova N. G. Dorofeeva Y. B. et al. (2017). Analysis of gut microbiota in patients with Parkinson’s disease. Bull. Exp. Biol. Med. 162, 734–737. doi: 10.1007/s10517-017-3700-7, PMID: 28429209
  106. Plovier H. Everard A. Druart C. Depommier C. Van Hul M. Geurts L. et al. (2017). A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med. 23, 107–113. doi: 10.1038/nm.4236, PMID: 27892954
  107. Poewe W. (2008). Non-motor symptoms in Parkinson’s disease. Eur. J. Neurol. 15, 14–20. doi: 10.1111/j.1468-1331.2008.02056.x, PMID: 18353132
  108. Poewe W. Seppi K. Tanner C. M. Halliday G. M. Brundin P. Volkmann J. et al. (2017). Parkinson disease. Nat. Rev. Dis. Prim. 3:17013. doi: 10.1038/nrdp.2017.13
  109. Quast C. Pruesse E. Yilmaz P. Gerken J. Schweer T. Yarza P. et al. (2013). The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 41, D590–D596. doi: 10.1093/nar/gks1219
  110. Rajilić-Stojanović M. Biagi E. Heilig H. G. H. J. Kajander K. Kekkonen R. A. Tims S. et al. (2011). Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141, 1792–1801. doi: 10.1053/j.gastro.2011.07.043, PMID: 21820992
  111. Rees R. N. Acharya A. P. Schrag A. Noyce A. J. (2018). An early diagnosis is not the same as a timely diagnosis of Parkinson’s disease. F1000Res 7:1106. doi: 10.12688/f1000research.14528.1, PMID: 30079229
  112. Ren T. Gao Y. Qiu Y. Jiang S. Zhang Q. Zhang J. et al. (2020). Gut microbiota altered in mild cognitive impairment compared with Normal cognition in sporadic Parkinson’s disease. Front. Neurol. 11:137. doi: 10.3389/fneur.2020.00137, PMID: 32161568
  113. Reunanen J. Kainulainen V. Huuskonen L. Ottman N. Belzer C. Huhtinen H. et al. (2015). Akkermansia muciniphila adheres to enterocytes and strengthens the integrity of the epithelial cell layer. Appl. Environ. Microbiol. 81, 3655–3662. doi: 10.1128/AEM.04050-14, PMID: 25795669
  114. Rohart F. Gautier B. Singh A. Lê Cao K.-A. (2017). mixOmics: an R package for ‘omics feature selection and multiple data integration. PLoS Comput. Biol. 13:e1005752. Available at:. doi: 10.1371/journal.pcbi.1005752, PMID: 29099853
  115. Romano S. Savva G. M. Bedarf J. R. Charles I. G. Hildebrand F. Narbad A. (2021). Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation. Npj Park. Dis 7:27. doi: 10.1038/s41531-021-00156-z
  116. Rusch C. Beke M. Tucciarone L. Nieves C. J. Ukhanova M. Tagliamonte M. S. et al. (2021). Mediterranean diet adherence in people with Parkinson’s disease reduces constipation symptoms and changes fecal microbiota after a 5-week single-arm pilot study. Front. Neurol. 12:794640. doi: 10.3389/fneur.2021.794640, PMID: 35002935
  117. Sarah V. Vanessa P. Marta M. Silvia P. Roberto C. Paolo U. et al. (2020). Gut microbiota and metabolome alterations associated with Parkinson’s disease. mSystems 5:e00561-20. doi: 10.1128/msystems.00561-20
  118. Shen T. Yue Y. He T. Huang C. Qu B. Lv W. et al. (2021). The association between the gut microbiota and Parkinson’s disease, a Meta-analysis. Front. Aging Neurosci. 13:636545. doi: 10.3389/fnagi.2021.636545, PMID: 33643026
  119. Shi J. Wang Y. Chen D. Xu X. Li W. Li K. et al. (2023). The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson’s disease. Appl. Microbiol. Biotechnol. 107, 1917–1929. doi: 10.1007/s00253-023-12410-w, PMID: 36795141
  120. Shrimanker I. Tadi P. Schoo C. Sánchez-Manso J. C. (2024). Parkinsonism. Treasure Island, FL. Available online at: https://pubmed.ncbi.nlm.nih.gov/31194381/
  121. Silva Y. P. Bernardi A. Frozza R. L. (2020). The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front. Endocrinol. 11:25. doi: 10.3389/fendo.2020.00025
  122. Su D. Cui Y. He C. Yin P. Bai R. Zhu J. et al. (2025). Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of global burden of disease study 2021. BMJ 388:e080952. doi: 10.1136/bmj-2024-080952, PMID: 40044233
  123. Sun X. Xue L. Wang Z. Xie A. (2022). Update to the treatment of Parkinson’s disease based on the gut-brain axis mechanism. Front. Neurosci. 16:878239. doi: 10.3389/fnins.2022.878239
  124. Sun H. Zhao F. Liu Y. Ma T. Jin H. Quan K. et al. (2022). Probiotics synergized with conventional regimen in managing Parkinson’s disease. NPJ Parkinsons Dis. 8:62. doi: 10.1038/s41531-022-00327-6, PMID: 35610236
  125. Surmeier D. J. Obeso J. A. Halliday G. M. (2017). Selective neuronal vulnerability in Parkinson disease. Nat. Rev. Neurosci. 18, 101–113. doi: 10.1038/nrn.2016.178, PMID: 28104909
  126. Takahashi K. Nishida A. Fujimoto T. Fujii M. Shioya M. Imaeda H. et al. (2016). Reduced abundance of butyrate-producing Bacteria species in the fecal microbial Community in Crohn’s disease. Digestion 93, 59–65. doi: 10.1159/000441768, PMID: 26789999
  127. Tedjo D. I. Jonkers D. M. A. E. Savelkoul P. H. Masclee A. A. van Best N. Pierik M. J. et al. (2015). The effect of sampling and storage on the fecal microbiota composition in healthy and diseased subjects. PLoS One 10:e0126685. doi: 10.1371/journal.pone.0126685, PMID: 26024217
  128. Toh T. S. Chong C. W. Lim S.-Y. Bowman J. Cirstea M. Lin C.-H. et al. (2022). Gut microbiome in Parkinson’s disease: new insights from meta-analysis. Parkinsonism Relat. Disord. 94, 1–9. doi: 10.1016/j.parkreldis.2021.11.017, PMID: 34844021
  129. Unger M. M. Spiegel J. Dillmann K.-U. Grundmann D. Philippeit H. Bürmann J. et al. (2016). Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat. Disord. 32, 66–72. doi: 10.1016/j.parkreldis.2016.08.019, PMID: 27591074
  130. Văcărean-Trandafir I. C. Amărandi R.-M. Ivanov I. C. Dragoș L. M. Mențel M. Iacob Ş. et al. (2024). Impact of antibiotic prophylaxis on gut microbiota in colorectal surgery: insights from an Eastern European stewardship study. Front. Cell. Infect. Microbiol. 14:1468645. doi: 10.3389/fcimb.2024.1468645
  131. Văcărean-Trandafir I. C. Amărandi R.-M. Ivanov I. C. Iacob Ş. Muşină A.-M. Bărgăoanu E.-R. et al. (2023). The impact of cefuroxime prophylaxis on human intestinal microbiota in surgical oncological patients. Front. Microbiomes 1:1092771. doi: 10.3389/frmbi.2022.1092771
  132. Vandeputte D. Falony G. Vieira-Silva S. Tito R. Y. Joossens M. Raes J. (2016). Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut 65, 57–62. doi: 10.1136/gutjnl-2015-309618, PMID: 26069274
  133. Wachamo S. Gaultier A. (2025). The emerging role of microbiota derived SCFAs in neurodegenerative disorders. Brain Behav. Immun. 46:101012. doi: 10.1016/j.bbih.2025.101012, PMID: 40502529
  134. Wallen Z. D. Appah M. Dean M. N. Sesler C. L. Factor S. A. Molho E. et al. (2020). Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. NPJ Parkinsons Dis. 6:11. doi: 10.1038/s41531-020-0112-6, PMID: 32566740
  135. Wei X. Tao J. Xiao S. Jiang S. Shang E. Zhu Z. et al. (2018). Xiexin Tang improves the symptom of type 2 diabetic rats by modulation of the gut microbiota. Sci. Rep. 8:3685. doi: 10.1038/s41598-018-22094-2, PMID: 29487347
  136. Weis S. Schwiertz A. Unger M. M. Becker A. Faßbender K. Ratering S. et al. (2019). Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota. NPJ Parkinsons Dis. 5:28. doi: 10.1038/s41531-019-0100-x, PMID: 31815177
  137. Wickham H. (2016). ggplot2: elegant graphics for data analysis (Cham: Springer).
  138. Willis A. D. (2019). Rarefaction, alpha diversity, and statistics. Front. Microbiol. 10:2407. doi: 10.3389/fmicb.2019.02407, PMID: 31708888
  139. Yan Z. Yang F. Cao J. Ding W. Yan S. Shi W. et al. (2021). Alterations of gut microbiota and metabolome with Parkinson’s disease. Microb. Pathog. 160:105187. doi: 10.1016/j.micpath.2021.105187
  140. Zapała B. Stefura T. Wójcik-Pędziwiatr M. Kabut R. Bałajewicz-Nowak M. Milewicz T. et al. (2021). Differences in the composition of gut microbiota between patients with Parkinson’s disease and healthy controls: a cohort study. J. Clin. Med. 10:5698. doi: 10.3390/jcm10235698, PMID: 34884399
  141. Zhang K. Paul K. C. Jacobs J. P. Chou H.-C. L. Duarte Folle A. Del Rosario I. et al. (2022). Parkinson’s disease and the gut microbiome in rural California. J. Parkinsons Dis. 12, 2441–2452. doi: 10.3233/JPD-223500
  142. Zhang S. Wang R. Li D. Zhao L. Zhu L. (2021). Role of gut microbiota in functional constipation. Gastroenterol. Rep. 9, 392–401. doi: 10.1093/gastro/goab035, PMID: 34733524
  143. Zhang F. Yue L. Fang X. Wang G. Li C. Sun X. et al. (2020). Altered gut microbiota in Parkinson’s disease patients/healthy spouses and its association with clinical features. Parkinsonism Relat. Disord. 81, 84–88. doi: 10.1016/j.parkreldis.2020.10.034, PMID: 33099131
  144. Zhang M. Zhai Z. Yang B. He L. Wang J. Dai W. et al. (2023). Exploring the alteration of gut microbiota and brain function in gender-specific Parkinson’s disease based on metagenomic sequencing. Front. Aging Neurosci. 15:1148546. doi: 10.3389/fnagi.2023.1148546, PMID: 37502423

Issue

Frontiers in Neuroscience, vol. 19, 2025, Albania, https://doi.org/10.3389/fnins.2025.1654995

Вид: статия в списание, публикация в реферирано издание, индексирана в Scopus